The Journal of Targeted Therapies in Cancer

It is estimated that 1 in 63 individuals in the United States will develop renal cell carcinoma (RCC), making it among the most common cancers in the country.
Hepatocellular cancer (HCC) is a rapidly fatal malignancy that is often diagnosed at an advanced stage when it is not curable. Despite a rise in incidence, this cancer is not as common in the Western world as it is in Asia and Africa.
Therapies targeted to tumor biology hold the promise of improved outcomes for patients with breast cancer.
The 5-year survival rate for patients with metastatic colorectal cancer (CRC) remains dismal. Liver metastases are a particularly common occurrence, developing in approximately half of all patients with colorectal cancer.
Cervical cancer screening based on identification of human papillomavirus (HPV) outperformed primary liquid cytology for detection of high-grade cervical intraepithelial neoplasia (CIN).
Dacomitinib has demonstrated potential as treatment for a subset of patients with recurrent squamous cell carcinoma of the head and neck (SCCHN).
The bromodomain inhibitor, OTX015, may have use in the treatment of hematologic malignancies, including acute leukemia and other hematologic malignancies that include lymphomas and multiple myeloma.
JTT Articles
Dacomitinib Shows Responses in Subset of Head and Neck Cancer
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
Graft Versus Host Disease for the General Oncologist
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.